Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients

Professor Meletios Dimopoulos - University of Athens, Greece
Pomalidomide with low-dose vs. high-dose dexamathasone in refractory patients ( Professor Meletios Dimopoulos - University of Athens, Greece )
16 Dec 2012

MLN9708 in combination with lenalidomide and dexamethasone

Dr Shaji Kumar - Mayo Clinic, Rochester, USA
MLN9708 in combination with lenalidomide and dexamethasone ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
16 Dec 2012

History of epidermal stem cell use in the clinical setting

Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy
History of epidermal stem cell use in the clinical setting ( Prof Michele De Luca - University of Modena e Reggio Emilia, Modena, Italy )
14 Dec 2012

The AZURE translational study

Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK
The AZURE translational study ( Prof Robert Coleman - Weston Park Hospital, University of Sheffield, UK )
14 Dec 2012

Diagnosis of blood cancer after a breast cancer diagnosis

Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA
Diagnosis of blood cancer after a breast cancer diagnosis ( Prof Antonio Wolff - The Johns Hopkins Hospital, Baltimore, USA )
14 Dec 2012

Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia

Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA
Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia ( Dr Jorge Cortes - MD Anderson Cancer Center, Houston, TX, USA )
13 Dec 2012

HDAC inhibition sensitises triple-negative breast cancer cells to PARP inhibition

Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA
HDAC inhibition sensitises triple-negative breast cancer cells to PARP inhibition ( Dr Kapil Bhalla - University of Kansas Cancer Center, Kansas City, USA )
13 Dec 2012

Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant

Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA
Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant ( Dr Mark Levis - Johns Hopkins Medicine, Baltimore, USA )
13 Dec 2012

A need for clarity in clinical trial end points

Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA
A need for clarity in clinical trial end points ( Dr Clifford Hudis – Memorial Sloan Kettering Cancer Center, New York, USA )
13 Dec 2012

The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab

Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA
The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab ( Prof Jan Burger - The University of Texas MD Anderson Cancer Center, Houston, USA )
13 Dec 2012

Uncovering new targets for treatment of chronic lymphocytic leukaemia

Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA
Uncovering new targets for treatment of chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University Comprehensive Cancer Center, Columbus, USA )
13 Dec 2012

Neratinib shows beneficial effects in the treatment of HER2 mutated breast cancer

Prof Ron Bose – Washington University School of Medicine, St. Louis, USA
Neratinib shows beneficial effects in the treatment of HER2 mutated breast cancer ( Prof Ron Bose – Washington University School of Medicine, St. Louis, USA )
12 Dec 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation